JP2021520380A5 - - Google Patents

Info

Publication number
JP2021520380A5
JP2021520380A5 JP2020554275A JP2020554275A JP2021520380A5 JP 2021520380 A5 JP2021520380 A5 JP 2021520380A5 JP 2020554275 A JP2020554275 A JP 2020554275A JP 2020554275 A JP2020554275 A JP 2020554275A JP 2021520380 A5 JP2021520380 A5 JP 2021520380A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
hct
years
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020554275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520380A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/025716 external-priority patent/WO2019195506A1/en
Publication of JP2021520380A publication Critical patent/JP2021520380A/ja
Publication of JP2021520380A5 publication Critical patent/JP2021520380A5/ja
Pending legal-status Critical Current

Links

JP2020554275A 2018-04-04 2019-04-04 ヒト臍帯組織由来の間葉系間質細胞を使用して自閉症スペクトラム障害を処置する方法 Pending JP2021520380A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652722P 2018-04-04 2018-04-04
US62/652,722 2018-04-04
PCT/US2019/025716 WO2019195506A1 (en) 2018-04-04 2019-04-04 Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells

Publications (2)

Publication Number Publication Date
JP2021520380A JP2021520380A (ja) 2021-08-19
JP2021520380A5 true JP2021520380A5 (https=) 2022-04-11

Family

ID=68101425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554275A Pending JP2021520380A (ja) 2018-04-04 2019-04-04 ヒト臍帯組織由来の間葉系間質細胞を使用して自閉症スペクトラム障害を処置する方法

Country Status (12)

Country Link
US (1) US12491210B2 (https=)
EP (1) EP3773486B1 (https=)
JP (1) JP2021520380A (https=)
KR (1) KR20210031853A (https=)
CN (1) CN112351785A (https=)
AU (1) AU2019247210A1 (https=)
BR (1) BR112020020295A2 (https=)
CA (1) CA3096033A1 (https=)
ES (1) ES2968823T3 (https=)
IL (1) IL277733B2 (https=)
SG (1) SG11202009805PA (https=)
WO (1) WO2019195506A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113057969A (zh) * 2021-03-09 2021-07-02 吴志新 一种间充质干细胞对儿童自闭症临床应用实验方法
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
US9347956B2 (en) 2010-12-16 2016-05-24 Autism Biotech Limited Biomarker and uses thereof in diagnosis, treatment of autism
AU2017235446A1 (en) 2016-03-16 2018-11-08 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy
US20170296588A1 (en) * 2016-04-19 2017-10-19 AngioStem, Inc. Mesenchymal stem cells derived from placental sources
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
US10987381B2 (en) 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis

Similar Documents

Publication Publication Date Title
US12205720B2 (en) Digital qualimetric biomarkers for cognition and movement diseases or disorders
Cirillo et al. Post-stroke remodeling processes in animal models and humans
Kouijzer et al. Neurofeedback treatment in autism. Preliminary findings in behavioral, cognitive, and neurophysiological functioning
Radmard et al. Evaluation of cerebellar ataxic patients
Kozlowski et al. The control of movement following traumatic brain injury
Mukherjee et al. Intensive rehabilitation combined with HBO2 therapy in children with cerebral palsy: a controlled longitudinal study
Modoni et al. Long-term safety and usefulness of mexiletine in a large cohort of patients affected by non-dystrophic myotonias
Preisler et al. Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease)
JP2021520380A5 (https=)
Man et al. Link between the skin and autism spectrum disorder
Tu et al. The neurobiological mechanisms underlying the effects of exercise interventions in autistic individuals
Rossi-Izquierdo et al. What could posturography tell us about balance in essential tremor?
JP2020510049A5 (https=)
Moore et al. Intensive teenage activity is associated with greater muscle hyperintensity on T1W magnetic resonance imaging in adults with dysferlinopathy
Miznerova et al. Virtual reality-based neuroproprioceptive physiotherapy in multiple sclerosis: a protocol for a double-arm randomised assessor-blinded controlled trial on upper extremity function, postural function and quality of life, with molecular and functional MRI assessment
Dziadkowiak et al. Establishing Diagnostic and Differential Diagnostic Criteria for Amyotrophic Lateral Sclerosis
Zoccolella et al. Neurophysiological indices for split phenomena: correlation with age and sex and potential implications in amyotrophic lateral sclerosis
Peyre et al. Computerized oculomotor training in dyslexia: A randomized, crossover clinical trial in pediatric population
Koszewicz et al. Motor fiber function in spinal muscular atrophy—analysis of conduction velocity distribution
Capece et al. Case Report: Laryngospasm as Initial Manifestation of Amyotrophic Lateral Sclerosis in a Long-Survival Patient With Heterozygous p. D90A–SOD1 Mutation
Sharma et al. Amelioration of autism by autologous bone marrow mononuclear cells and neurorehabilitation: a case report
Alaydin et al. The Role of the Cutaneous Silent Period in the Electrophysiological Diagnosis of Guillain–Barré Syndrome
Czachowski Functional disorders–new proposals for definition, classifications, etiology and therapies
Van Oorsouw et al. Side effects of contingent shock treatment
US20180289655A1 (en) Methods and Compositions for the Intravenous Administration of Fumarates for the Treatment of Neurological Diseases